- Home
- APGE vs DNLI Comparison
APGE vs DNLI Comparison
Compare APGE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- DNLI
- Stock Information
- Founded
- APGE 2022
- DNLI 2013
- Country
- APGE United States
- DNLI United States
- Employees
- APGE N/A
- DNLI N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APGE Health Care
- DNLI Health Care
- Exchange
- APGE Nasdaq
- DNLI Nasdaq
- Market Cap
- APGE 2.1B
- DNLI 1.8B
- IPO Year
- APGE 2023
- DNLI 2017
- Fundamental
- Price
- APGE $33.11
- DNLI $12.74
- Analyst Decision
- APGE Strong Buy
- DNLI Strong Buy
- Analyst Count
- APGE 4
- DNLI 16
- Target Price
- APGE $91.33
- DNLI $37.57
- AVG Volume (30 Days)
- APGE 802.7K
- DNLI 1.7M
- Earning Date
- APGE 05-12-2025
- DNLI 05-06-2025
- Dividend Yield
- APGE N/A
- DNLI N/A
- EPS Growth
- APGE N/A
- DNLI N/A
- EPS
- APGE N/A
- DNLI N/A
- Revenue
- APGE N/A
- DNLI N/A
- Revenue This Year
- APGE N/A
- DNLI N/A
- Revenue Next Year
- APGE $743.14
- DNLI $372.05
- P/E Ratio
- APGE N/A
- DNLI N/A
- Revenue Growth
- APGE N/A
- DNLI N/A
- 52 Week Low
- APGE $26.20
- DNLI $10.57
- 52 Week High
- APGE $63.50
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- APGE 45.63
- DNLI 42.15
- Support Level
- APGE $31.38
- DNLI $12.37
- Resistance Level
- APGE $34.23
- DNLI $13.63
- Average True Range (ATR)
- APGE 3.28
- DNLI 1.24
- MACD
- APGE -0.18
- DNLI 0.23
- Stochastic Oscillator
- APGE 54.22
- DNLI 50.94
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.